Literature DB >> 22380773

Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.

Vinayaka Kotraiah1, Diego Pallares, Deanna Toema, Dehe Kong, Eric Beausoleil.   

Abstract

The highly similar aldehyde dehydrogenase isozymes (ALDH1A1 and ALDH2) have been implicated in the metabolism of toxic biogenic aldehydes such as 3,4-dihydroxyphenylacetaldehyde (DOPAL) and 4-hydroxy-2E-nonenal. We report the down-regulation of ALDH1A1 mRNA found in substantia nigra tissue of human Parkinson's disease (PD) samples using the Genome-Wide SpliceArray(™) (GWSA(™)) technology. Since DOPAL can rapidly inactivate ALDH1A1 in vitro, we set up a DOPAL-induced ALDH1A1 inactivation assay and used this assay to demonstrate that Alda-1, a compound originally identified as an activator of ALDH2, can also activate ALDH1A1. We carried out a virtual screening of 19,943 compounds and the top 21 hits from this screen were tested in the DOPAL inactivation assay with ALDH1A1 which led to identification of an activator as well as two inhibitors among these hits. These findings represent an attractive starting point for developing higher potency activator compounds that may have utility in restoring the metabolism of DOPAL in PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22380773     DOI: 10.3109/14756366.2011.653353

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  8 in total

Review 1.  Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.

Authors:  Che-Hong Chen; Julio Cesar Batista Ferreira; Eric R Gross; Daria Mochly-Rosen
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 2.  Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.

Authors:  Edna Grünblatt; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2014-10-09       Impact factor: 3.575

3.  Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.

Authors:  Robert A Parise; Jan H Beumer; Dana M Clausen; Lora H Rigatti; Judy A Ziegler; Maura Gasparetto; Clayton A Smith; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2013-09-24       Impact factor: 3.333

4.  Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism.

Authors:  Ching-Chi Chiu; Tu-Hsueh Yeh; Szu-Chia Lai; Yah-Huei Wu-Chou; Che-Hong Chen; Daria Mochly-Rosen; Yin-Cheng Huang; Yu-Jie Chen; Chao-Lang Chen; Ya-Ming Chang; Hung-Li Wang; Chin-Song Lu
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

5.  Reduced aldehyde dehydrogenase expression in preeclamptic decidual mesenchymal stem/stromal cells is restored by aldehyde dehydrogenase agonists.

Authors:  Gina D Kusuma; Mohamed H Abumaree; Anthony V Perkins; Shaun P Brennecke; Bill Kalionis
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 6.  The Role of Lipoxidation in the Pathogenesis of Diabetic Retinopathy.

Authors:  Josy Augustine; Evan P Troendle; Peter Barabas; Corey A McAleese; Thomas Friedel; Alan W Stitt; Tim M Curtis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-18       Impact factor: 5.555

7.  Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats.

Authors:  Jie Sun; Chao He; Qiu-Xin Yan; Hong-Dan Wang; Ke-Xin Li; Xun Sun; Yan Feng; Rong-Rong Zha; Chang-Peng Cui; Xue Xiong; Shan Gao; Xue Wang; Rui-Xue Yin; Guo-Fen Qiao; Bai-Yan Li
Journal:  CNS Neurosci Ther       Date:  2021-01-21       Impact factor: 5.243

8.  Computer-Aided Drug Design (CADD) to De-Orphanize Marine Molecules: Finding Potential Therapeutic Agents for Neurodegenerative and Cardiovascular Diseases.

Authors:  Laura Llorach-Pares; Alfons Nonell-Canals; Conxita Avila; Melchor Sanchez-Martinez
Journal:  Mar Drugs       Date:  2022-01-05       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.